$Jaguar Health (JAGX.US)$
I very much look forward to providing an overview of Magdalena at this conference and meeting with potential partners and investors at this event," Dr. Brunke said. "We expect Magdalena's lead botanical drug candidate, MB2500, to soon be IND-enabled for one of the following indications: cognitive deficit in schizophrenia or executive ...

$Jaguar Health (JAGX.US)$
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Thursday, 6th February at 10:00 am
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026
SAN F...

$Jaguar Health (JAGX.US)$
Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Monday, 3rd February at 9:30 am
Trial taking place at Sheikh Khalifa Medical City, a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi
Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the F...

$Jaguar Health (JAGX.US)$ Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application With USPTO
Accesswire· 4 mins ago

$Jaguar Health (JAGX.US)$
Jaguar Health Supports Evaluation of FDA-Approved Crofelemer to Address GI Side Effects of GLP-1 and Other Weight Loss Therapies: Files Patent Application with USPTO
Wednesday, 29th January at 8:30 am
Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85%
Crofelemer, approved by the FDA under the brand n...

$Jaguar Health (JAGX.US)$
Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025
Wednesday, 22nd January at 9:00 am
Trial taking place at Sheikh Khalifa Medical City, a flagship tertiary hospital in the United Arab Emirates
POC data generated from this study could potentially lead to reimbursed early patient ac...